Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This groundbreaking drug, categorized as a dual GLP-1 and GIP receptor agonist, shows promising results in investigations. By activating these receptors, Retatrutide reduces hunger pangs, {promotesglucose regulation, and u